{"id":"NCT00463346","sponsor":"Yale University","briefTitle":"Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism","officialTitle":"Treatment With Acamprosate in Patients With Schizophrenia and Comorbid Alcoholism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2007-04-20","resultsPosted":"2016-01-15","lastUpdate":"2020-03-31"},"enrollment":23,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alcohol Dependence","Schizophrenia"],"interventions":[{"type":"DRUG","name":"Acamprosate","otherNames":["Campral"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Acamprosate","type":"EXPERIMENTAL"},{"label":"placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The aim of this study is to evaluate the safety and efficacy of acamprosate for patients with alcohol dependence and comorbid schizophrenia spectrum disorders.\n\n* 1: Relative to placebo, acamprosate will significantly increase cumulative days of abstinence in recently detoxified alcohol dependent schizophrenia patients measured by Timeline Follow-Back (TLFB) method.\n* 2: Acamprosate will have no significant effect on the psychotic symptoms in schizophrenia patients with alcohol dependence as measured by the Positive and Negative Syndrome Scale (PANSS).","primaryOutcome":{"measure":"Number of Drinking Days","timeFrame":"12 weeks","effectByArm":[{"arm":"Acamprosate","deltaMin":10.7,"sd":17.11},{"arm":"Placebo","deltaMin":7.6,"sd":11.5}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":12},"commonTop":[]}}